Climb Bio, Inc. SEC filings CLYM
Climb Bio, Inc. has 325 filings in SEC EDGAR's recent list, going back to Feb 19, 2019. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 5, 2026 | — |
| S-3ASR | Automatic shelf registration | Nov 5, 2026 | — |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 28, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 27, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Sep 30, 2026 | Sep 28, 2026 |
| 4 | Insider transaction | Sep 17, 2026 | Sep 15, 2026 |
| 144 | Notice of proposed sale | Sep 15, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 3, 2026 | Sep 3, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 8, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 7, 2026 | — |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jul 1, 2026 | Jun 29, 2026 |
| 3 | Initial insider ownership | Jul 1, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 1, 2026 | Jun 29, 2026 |
| 4 | Insider transaction | Jun 30, 2026 | Jun 27, 2026 |
| 144 | Notice of proposed sale | Jun 30, 2026 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jun 12, 2026 | Jun 11, 2026 |
| 424B5 | Prospectus supplement | Jun 12, 2026 | — |
| 8-K |
Current report
Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| EFFECT | Filing | Jun 9, 2026 | — |
| 424B3 | Prospectus | Jun 9, 2026 | — |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 8, 2026 | Jun 5, 2026 |
| CORRESP | Letter to the SEC | Jun 5, 2026 | — |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | Jun 5, 2026 |
| UPLOAD | Letter from the SEC | Jun 4, 2026 | — |
| S-3 | Shelf registration | May 29, 2026 | — |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 5, 2026 | May 5, 2026 |
| D | Filing | May 4, 2026 | — |
| 4 | Insider transaction | Apr 29, 2026 | Apr 29, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 29, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Apr 28, 2026 | Apr 27, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 5, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2026 | Jun 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 3, 2026 | Apr 1, 2026 |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| 10-K | Annual report | Mar 5, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 4 | Insider transaction | Feb 27, 2026 | Feb 25, 2026 |
| 144 | Notice of proposed sale | Feb 25, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 17, 2026 | — |
| 4 | Insider transaction | Feb 17, 2026 | Feb 12, 2026 |
| 144 | Notice of proposed sale | Feb 12, 2026 | — |
| 4 | Insider transaction | Jan 8, 2026 | Jan 6, 2026 |
| 4 | Insider transaction | Jan 8, 2026 | Jan 6, 2026 |
| 4 | Insider transaction | Jan 8, 2026 | Jan 6, 2026 |
| 4 | Insider transaction | Jan 8, 2026 | Jan 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 8, 2026 | Jan 8, 2026 |
| 4 | Insider transaction | Jan 7, 2026 | Jan 5, 2026 |
| 8-K |
Current report
Other events
|
Dec 31, 2025 | Dec 31, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 15, 2025 | — |
| 4 | Insider transaction | Dec 15, 2025 | Dec 11, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 11, 2025 | Dec 11, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Other events
|
Oct 17, 2025 | Oct 17, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 16, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 7, 2025 | — |
| 4 | Insider transaction | Oct 1, 2025 | Oct 1, 2025 |
| 3 | Initial insider ownership | Oct 1, 2025 | Oct 1, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 1, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2025 | Sep 29, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 18, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 4 | Insider transaction | Aug 11, 2025 | Aug 7, 2025 |
| 4 | Insider transaction | Jul 1, 2025 | Jun 27, 2025 |
| 4 | Insider transaction | Jul 1, 2025 | Jun 27, 2025 |
| 3 | Initial insider ownership | Jun 23, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 17, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 18, 2025 |
| 3 | Initial insider ownership | Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 5, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 4, 2025 |
| DEFA14A | Additional proxy material | May 23, 2025 | — |
| 8-K |
Current report
Officer or director change
|
May 23, 2025 | May 23, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Apr 1, 2025 | Mar 31, 2025 |
| 4 | Insider transaction | Apr 1, 2025 | Mar 28, 2025 |
| 4 | Insider transaction | Apr 1, 2025 | Mar 28, 2025 |
| 3 | Initial insider ownership | Apr 1, 2025 | Mar 28, 2025 |
| 3 | Initial insider ownership | Apr 1, 2025 | Mar 28, 2025 |
| S-8 | Employee stock plan registration | Apr 1, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Apr 1, 2025 | Mar 27, 2025 |
| 4 | Insider transaction | Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Material agreement, Results of operations
|
Mar 25, 2025 | Mar 25, 2025 |
| 424B5 | Prospectus supplement | Mar 25, 2025 | — |
| 10-K | Annual report | Mar 25, 2025 | Dec 31, 2024 |
| 4 | Insider transaction | Mar 20, 2025 | Mar 18, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2025 | — |
| 4 | Insider transaction | Jan 15, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 15, 2025 | Jan 13, 2025 |
| 4 | Insider transaction | Jan 15, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Jan 10, 2025 | Jan 8, 2025 |
| 4 | Insider transaction | Jan 3, 2025 | Jan 1, 2025 |
| 4 | Insider transaction | Dec 20, 2024 | Dec 18, 2024 |
| EFFECT | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 20, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 4 | Insider transaction | Nov 12, 2024 | Nov 11, 2024 |
| 3 | Initial insider ownership | Nov 12, 2024 | Nov 8, 2024 |
| S-3 | Shelf registration | Nov 12, 2024 | — |
| 8-K |
Current report
Results of operations, Other events
|
Nov 12, 2024 | Nov 12, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Oct 2, 2024 | Oct 2, 2024 |
| 4 | Insider transaction | Sep 20, 2024 | Sep 18, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2024 | Aug 23, 2024 |
| 4 | Insider transaction | Aug 26, 2024 | Aug 26, 2024 |
| 3 | Initial insider ownership | Aug 26, 2024 | Aug 26, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 26, 2024 | Aug 26, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Aug 16, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Aug 14, 2024 | — |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Jul 23, 2024 | — |
| 4 | Insider transaction | Jul 23, 2024 | Jul 19, 2024 |
| 424B3 | Prospectus | Jul 23, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| 4 | Insider transaction | Jul 19, 2024 | Jul 17, 2024 |
| UPLOAD | Letter from the SEC | Jul 18, 2024 | — |
| 4 | Insider transaction | Jul 17, 2024 | Jul 16, 2024 |
| 4 | Insider transaction | Jul 16, 2024 | Jul 12, 2024 |
| S-3 | Shelf registration | Jul 12, 2024 | — |
| 4 | Insider transaction | Jul 11, 2024 | Jul 9, 2024 |
| 4 | Insider transaction | Jul 9, 2024 | Jul 5, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 1, 2024 |
| D | Filing | Jul 2, 2024 | — |
| D | Filing | Jul 2, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Jul 2, 2024 | — |
| 4 | Insider transaction | Jul 1, 2024 | Jun 27, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Jul 1, 2024 | — |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 28, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 27, 2024 |
| 4 | Insider transaction | Jun 27, 2024 | Jun 27, 2024 |
| 3 | Initial insider ownership | Jun 27, 2024 | Jun 27, 2024 |
| 3 | Initial insider ownership | Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Regulation FD disclosure, Other events
|
Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 26, 2024 | Jun 26, 2024 |
| 4 | Insider transaction | Jun 21, 2024 | Jun 18, 2024 |
| DEFA14A | Additional proxy material | Jun 14, 2024 | — |
| DEFA14A | Additional proxy material | Jun 12, 2024 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 12, 2024 | Jun 12, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Jun 6, 2024 | — |
| ARS | Annual report to shareholders | Jun 4, 2024 | Dec 31, 2023 |
| DEFM14A | Filing | Jun 4, 2024 | — |
| PREM14A | Filing | May 17, 2024 | May 17, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | May 17, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | May 17, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| SC 13G | Ownership over 5% (passive) | May 7, 2024 | — |
| 10-K/A | Amended annual report | Apr 29, 2024 | Dec 31, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Apr 12, 2024 | — |
| DEFA14A | Additional proxy material | Apr 11, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Regulation FD disclosure
|
Apr 11, 2024 | Apr 10, 2024 |
| 4 | Insider transaction | Apr 8, 2024 | Apr 5, 2024 |
| S-8 | Employee stock plan registration | Mar 28, 2024 | — |
| 10-K | Annual report | Mar 28, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Mar 20, 2024 | Mar 18, 2024 |
| 8-K |
Current report
Other events
|
Mar 19, 2024 | Mar 14, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 18, 2024 | — |
| 4 | Insider transaction | Mar 4, 2024 | Sep 20, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 17, 2023 | — |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLYM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wellesley Hills, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1768446
- Former names
- Eliem Therapeutics, Inc. (until Sep 20, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.